• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    M

    Max Healthcare

    EST. 2001
    403论文总数
    5,994引用总数

    Max Healthcare Institute Limited is a hospital chain based in New Delhi, India. Max Healthcare owns and operates healthcare facilities across the National Capital Region (NCR) of Delhi, North India, and the western port city of Mumbai.

    论文量&引用量时间轴

    机构学者

    论文(403)

    年份
    起
    –
    止
    排序
    1Treatment Algorithm for Patients with Obesity in India: A Joint Consensus by Endocrine Society of India and Obesity Surgeons Society of India.
    Sarfaraz Jalil Baig, Aparna Govil Bhaskar,Chetan Parmar,Randeep Wadhawan,Sumeet Shah, Shehla Shaikh,Nitin Kapoor,Sambit Das, KVS Harikumar, Narendra Kotwal,Abhamoni Baro,Abhishek Katakwar,

    Obesity is a global health crisis affecting developing nations, including India. The management of obesity continues to evolve with newer drugs, metabolic and bariatric surgery and endoscopic interventions, requiring family physicians and specialists to adapt their clinical practice accordingly. There is an urgent need for a standardized algorithm to diagnose, stage, and treat obesity. The Endocrine Society of India (ESI) and the Obesity Surgeons Society of India (OSSI) appointed a steering committee to develop an evidence-based algorithm for managing patients with obesity in India. This was put to vote by 80 specialists (38 from OSSI and 42 from ESI) in a physical meeting. A proposed stage-wise algorithm based on Edmonton Obesity Staging System, Asian definition of obesity, and resources in India, received 100

    2026Obesity Surgery(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Multiscale Predictive Cellular Modeling: Integrating Hypothesis Grammars, Digital Twins, and Multi-Omics for in Silico Oncology and Precision Theranostics
    S. T. Gopukumar, Dyumn Dwivedi,Mohamed Rahamathulla, Mohammed Muqtader Ahmed, Tanveen Kaur Soni, Praveen Ganesh Natarajan, S. Ramkanth, Arpita Mitra, Uddalak Das

    Predictive multiscale cellular modeling is emerging as a consequential direction in precision medicine, converging hypothesis grammars, digital twins, and integrative genomics to interrogate tumor-immune dynamics, therapeutic resistance, and cellular plasticity. This perspective synthesizes recent progress across these domains and critically maps their translational potential alongside their current limitations. Hypothesis grammars translate mechanistic theories into executable agent-based models (ABMs) and hybrid ODE-PDE systems, enabling rapid in silico hypothesis testing while lowering the authoring barrier for domain scientists. Patient-specific digital twins, driven by multi-omics data, employ stochastic ensemble methods to simulate clonal evolution and microenvironmental interactions, though prospective clinical validation of these capabilities remains at an early stage. Integrative genomics, leveraging algorithms such as SCODE and SimiC, infers causal gene regulatory networks (GRNs) using Bayesian variational autoencoders, embedding dynamic intracellular logic into tissue-scale simulations. Emerging applications include in silico oncology trials for optimizing checkpoint blockade and combination therapies. Large language models are being explored to enhance rule induction, while FAIR-compliant digital cell repositories aim to ensure reproducibility and reuse. Verification, validation, and uncertainty quantification (VVUQ) via Sobol sensitivity analysis and Kennedy-O’Hagan calibration are identified as essential components for addressing non-identifiability and supporting regulatory credibility. Federated learning is discussed as a means of mitigating privacy and bias concerns in multi-institutional settings. Together, these converging approaches outline a plausible pathway toward virtual clinical trials and adaptive theranostics, contingent on the prospective validation, data infrastructure, and governance frameworks that clinical deployment will require.

    2026Functional & Integrative Genomics(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Sometimes Less is More: on Sample Size in Medical Research.
    Abhaya Indrayan, Ashok Kumar Saxena,Rajeev Kumar Malhotra

    Large samples have well-known merits in empirical research where multiple factors are at work, some beyond control. Large samples also provide a precise estimate of the effect size, although they produce results for groups and not for individuals. Nonetheless, there are situations where intensive, in-depth, study of a few may be rewarding, particularly in medical research that focuses on basic mechanism rather than treatment effect. With extreme care, logical structure, advanced tools, and rigorous reasoning, many sources of variability can be minimized or eliminated. Thus, small samples tend to foster brilliance by focusing on improved decision making. Reduced cost, faster completion, and clinically relevant effect sizes are among other advantages. Many successful studies have been done on small samples. These merits of small sample studies in certain types of medical research deserve serious consideration.

    2026Journal of evaluation in clinical practice(2026)
    引用
    AI阅读
    加入学术空间
    4A Novel De Novo Splice-Site Variant in RPS26 Identified by Exome Sequencing in a Patient with Suspected Diamond-Blackfan Anemia
    Deepak Panwar, Atul Thatai

    Background: Diamond–Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome characterized by pure red cell aplasia and is commonly caused by variants in ribosomal protein genes. Variants in RPS26 are relatively uncommon, and splice-site changes in this gene are still underreported. Case Presentation: We describe a 17-month-old female who presented with severe anemia with clinical features suggestive of Diamond–Blackfan anemia. Whole Exome sequencing (WES) identified a novel heterozygous de novo canonical splice-site variant, NM_001029.5:c.182-1G>A in the RPS26 gene. The variant was absent from population databases, including gnomAD, and was also confirmed by Sanger sequencing. In silico analysis using SpliceAI predicted disruption of the canonical splice acceptor site along with activation of a cryptic splice site, suggesting a deleterious effect on normal splicing. However, RNA studies are needed to confirm the exact splicing outcome and to better understand how this variant affects RPS26 function. Based on ACMG/AMP guidelines, the variant was classified as likely pathogenic. Conclusion: This case contributes to the known mutational spectrum of RPS26 and highlights the value of exome sequencing in the molecular evaluation of patients with suspected DBA.

    2026Journal of Biochemical and Clinical Genetics(2026)
    引用
    AI阅读
    加入学术空间
    5Outcomes of Living-Donor Liver Transplantation in Patients with MELD Scores >40: A Propensity-Matched Analysis from a High-Volume Center
    H. Sharma, S. Gupta
    2026AMERICAN JOURNAL OF TRANSPLANTATION(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 403 篇论文

    合作机构(100)

    All India Institute of Medical Sciences合作论文 32
    Max Super Speciality Hospital,Max Healthcare合作论文 15
    Apollo Hospital, Indraprastha合作论文 10
    雅典国立和卡波迪斯蒂安大学合作论文 9
    Manipal Hospital合作论文 9
    Fortis Malar Hospital合作论文 9
    塔塔纪念医院合作论文 8
    弗吉尼亚大学合作论文 8
    Sanjay Gandhi 研究生医学院合作论文 8
    明尼苏达大学合作论文 8

    机构统计